We are excited to share the findings of a comprehensive study that sheds light on the safety and effectiveness of ocrelizumab in treating relapsing-remitting multiple sclerosis (RRMS) over an extended period. This is the longest follow-up study of ocrelizumab-treated patients with RRMS, spanning from 2008 to 2020.
The study confirmed the sustained efficacy of long-term ocrelizumab, with no new safety concerns identified. It's remarkable to note that even after longer interruptions of 6-month dosing cycles, most participants still maintained a reduced level of disease activity, and there was no evidence of rebound.
These findings offer hope to individuals living with RRMS, bringing us one step closer to enhancing their quality of life. With ocrelizumab's proven safety and effectiveness over an extensive follow-up period, we remain confident about its positive impact on the future of MS treatment.
